December 10, 2020
PA-18-935 - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
NOT-OD-20-118 - Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
National Human Genome Research Institute (NHGRI)
This purpose of this Notice of Special Interest (NOSI) is to inform the extramural community about NHGRI’s interest in supporting research on pressing public health questions that can uniquely be addressed by collaborative efforts of large international cohort studies. Specifically, this call is limited to coordinated efforts focused on the collection and analysis of data or samples from ancestrally diverse cohorts of individuals participating in the International Hundred Thousand+ Cohort Consortium.
Obesity is a major risk factor for leading causes of death including heart disease and stroke, diabetes, and some cancers, as well as disability due to osteoarthritis and other degenerative conditions. Worldwide, obesity has more than tripled since 1975, and most of the world’s population live in countries where more people die from obesity and being overweight than being underweight. Opioid use disorder has also become a public health crisis; globally, more than 100,000 people died of opioid overdose in 2017, while an estimated 1.7 million Americans suffered from opioid use disorders. Opioid use disorder, obesity, and numerous other risk factors are more prevalent in populations of lower socioeconomic status, including ethnic minorities and rural populations. Limited access to high-quality healthcare limits the potential to reduce these risk factors and ameliorate their adverse effects. Many of these factors are also associated with increased susceptibility to infection with the SARS-CoV2 virus and resultant morbidity and mortality from the illness it causes, COVID-19.
Applications in response to this NOSI are limited to active grants to network coordinating centers supported by the National Human Genome Research Institute (NHGRI).
Large international cohort studies such as those collaborating in the International Hundred Thousand+ Cohorts Consortium (IHCC, https://ihccglobal.org/) are uniquely positioned to address pressing public health questions on a global scale that no cohort can answer alone. Such questions include, but are not limited to, the etiology and impact of critical risk factors for morbidity and mortality such as obesity, lower socioeconomic status, minority status, poor access to health care, and global pandemics. Research topics responsive to this NOSI include, but are not limited to:
Funds may be used for the collection and analysis of data or samples from human cohorts of individuals participating in the IHCC. Expanding the representation of ancestrally and geographically diverse cohorts in these efforts, and improving methods for cost-efficient and secure analysis, are also strongly encouraged.
NHGRI strongly encourages investigators to promote the collection of comparable data across studies and to do so by incorporating measures from the PhenX Toolkit (www.phenxtoolkit.org) when applicable.
Eligible existing grants that can be revised in response to this NOSI are limited to network coordinating centers funded by NHGRI.
Application and Submission Information
Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents.
If approved, the document acknowledging that NHGRI will accept this greater than $250,000 direct costs per year application should be submitted in a cover letter along with the application.
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff listed on this NOSI well in advance of the application receipt date to better determine appropriateness and interest of the NHGRI.
Please direct all inquiries to:
Rongling Li, M.D., Ph.D
National Human Genome Research Institute